Clopidogrel responder status is uninfluenced by CYP2C19*2 in Danish patients with stroke.

ABSTRACT:

Background

Antiplatelet therapy is a cornerstone of secondary stroke prevention, but the responsiveness to antiplatelet medication varies among patients. Clopidogrel is a pro-drug that requires hepatic transformation to reach its active metabolite. Single nucleotide polymorphisms (SNPs) in key enzymes or the target adenosine diphosphate (ADP) receptor on the platelet surface are believed to be involved in clopidogrel-mediated platelet inhibition and decreased antiplatelet effect with high-on-treatment platelet reactivity (HTPR).

Objective

This study investigated whether specific SNPs in key hepatic enzymes (CYP2C19*2, *3, *17, CYP3A4*1G, and NR1I2) or the ADP receptor (PR2Y12) are associated with HTPR to clopidogrel.

Patients & methods

This observational study include

SUBMITTER: Rath CL 

PROVIDER: S-EPMC7769274 | biostudies-literature | 2020

REPOSITORIES: biostudies-literature